Advertisement
News
Advertisement

Radioimmunotherapy Could Potentially Eradicate Lingering HIV Infection

Tue, 12/03/2013 - 1:39am
Einstein

December 3, 2013 – (BRONX, NY) – Nearly nine million adults worldwide living with the human immunodeficiency virus (HIV) receive antiretroviral therapy. Although highly active antiretroviral therapy (HAART) keeps the virus from multiplying by killing the virus in the bloodstream, it does not cure patients infected with HIV because it does not completely eliminate the HIV-infected cells in which the virus can replicate.

Ekaterina Dadachova, Ph.D.
Ekaterina Dadachova, Ph.D.
New findings presented today at the annual meeting of the Radiological Society of North America (RSNA) by researchers at Albert Einstein College of Medicine of Yeshiva University show that radioimmunotherapy (RIT) could potentially eradicate HIV-infected  cells.

"There have been major strides in HIV treatment that slow disease progression, but we’re still searching for a permanent cure," said study leader Ekaterina Dadachova, Ph.D., professor of radiology and of microbiology & immunology. "To combat HIV, we need a method that will completely eliminate all HIV-infected cells without damaging non-infected cells."

In RIT, historically known as a cancer treatment, radioactive isotopes attached to antibodies selectively target and destroy cells. After the antibodies deliver the radioisotope to a specific target, such as a cancer cell or disease-causing microbe, the radioisotope delivers a lethal dose of radiation without harming healthy cells.

The research presented at RSNA builds off earlier work by Dr. Dadachova showing RIT could successfully target and destroy human immune cells infected with HIV. Now, Dr. Dadachova in collaboration with her colleagues Arturo Casadevall, M.D., Ph.D. and Barry Zingman, M.D., administered RIT to blood samples from 15 HIV patients treated with HAART at The AIDS Center at Montefiore, the University Hospital and academic medical center for Einstein. They found that RIT was able to specifically kill HAART-treated lymphocytes and reduce HIV infection to undetectable levels in the majority of samples.

"We found that radioimmunotherapy could kill HIV-infected cells both in blood samples that received antiretroviral treatment and within the central nervous system, demonstrating RIT offers real potential for being developed into an HIV cure."

-- Ekaterina Dadachova, Ph.D.

The Einstein researchers also investigated whether the RIT approach can reach HIV-infected cells in the brain and central nervous system. Current anti-retroviral therapy drugs do not efficiently penetrate the blood-brain barrier, a system of blood vessels that stops harmful substances from crossing into the brain. This is why many HIV patients treated with HAART often suffer from severe cognitive impairment. Using a laboratory model of the blood-brain barrier constructed of human cells and developed by Joan  Berman, Ph.D., they showed that the same radiolabeled antibodies used in earlier experiments could eliminate HIV-infected cells in the brain without damaging the barrier.

"We found that radioimmunotherapy could kill HIV-infected cells both in blood samples that received antiretroviral treatment  and within the central nervous system, demonstrating RIT offers real potential for being developed into an HIV cure," said Dr. Dadachova, who also holds the Sylvia and Robert S. Olnick Faculty Scholar in Cancer Research.

Dr. Zingman is professor of clinical medicine at Einstein and medical director of The AIDS Center at Montefiore. Dr. Casadevall is professor and chair of microbiology & immunology at Einstein and attending physician, medicine at Montefiore. Dr. Berman is professor of pathology and of microbiology & immunology at Einstein.

The experimental work was carried out by Alicia McFarren, M.D., a pediatric oncology fellow, and Dina Tsukrov, M.S., a graduate student. The team used a radionuclide supplied by the collaborators at the Institute for Transuranium Elements (ITU), Karlsruhe, Germany.

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading